MPN NEWS | March 18, 2008
03/18/2008 Cytopia Limited (ASX:CYT) has selected CYT387, a selective and potent JAK2 inhibitor, for formal preclinical development to treat myeloproliferative disorders (MPDs). This follows extensive laboratory experimentation and includes the recent demonstration of activity in an in-vivo model of myeloproliferative disease. Myeloproliferative disorders are a group of diseases including myelofibrosis, polycythemia vera (PV) and essential… Read More »CYTOPIA NOMINATES JAK2 CLINICAL CANDIDATE FOR MYELOPROLIFERATIVE DISORDERS
MPN NEWS | January 31, 2008
San Diego, CA – January 31, 2008 – TargeGen, Inc. today announced that the Company has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases. The V617F mutation of JAK2 is implicated in the pathogenesis of certain myeloproliferative diseases, including polycythemia… Read More »TARGEGEN ANNOUNCES INITIATION OF CLINICAL TRIAL OF JAK2 INHIBITOR TG101348 IN MYELOPROLIFERATIVE DISEASE PATIENTS
MPN NEWS | January 30, 2008
MELBOURNE, Australia, Jan. 30 /PRNewswire/ — Australian and New York based company Cytopia Limited announced today that its lead JAK2 inhibitor compound CYT387 has demonstrated potent activity in cells isolated from patients with myeloproliferative disorders (MPDs). MPDs are a series of diseases where there is over-production of particular cells within the blood stream. One of… Read More »JAK2 INHIBITOR SHOWS POTENT ACTIVITY IN CELLS FROM MPD PATIENTS
MPN NEWS | December 12, 2007
Published: December 12, 2007PRNewswire-USNewswire Atlanta, Dec. 5 — The American Society of Hematology (ASH), the world’s largest professional society of blood specialists, is honoring three scientists who have made notable contributions to the genetic understanding of disease. Carlo Croce, MD, will receive the Henry M. Stratton Medal, intended to honor an individual with a distinguished… Read More »TOP SCIENTISTS TO RECEIVE PRESTIGIOUS AWARDS FROM THE AMERICAN SOCIETY OF HEMATOLOGY
MPN NEWS | December 10, 2007
12/10/2007 2:06:40 PM Monday afternoon, Exelixis, Inc. (EXEL), a developer of therapies for the treatment of cancer and other serious diseases, announced data from an ongoing Phase 1 trial of XL019 to treat patients with myelofibrosis, a myeloproliferative disorder, or MPD. The primary objective of the trial is to determine the safety and tolerability of… Read More »EXELIXIS REPORTS DATA FROM ONGOING PHASE 1 STUDY OF XL019 TO TREAT MYELOFIBROSIS – UPDATE
MPN NEWS | December 10, 2007
Sunday December 10, 2007 8:00 am ET ORLANDO, Fla., Dec. 10 /PRNewswire/ — Both the cause and cure for polycythemia vera, a disorder of uncontrolled blood cell production, remain elusive, but researchers from the University of Florence, Italy, may be a step closer to both. Their findings are being presented today during the 48th Annual… Read More »GENE MUTATION PREDICTS OUTCOME IN BLOOD DISORDER
MPN NEWS | August 30, 2007
Novartis will collaborate with Incyte on the further development of two of Incyte Corp.’s compounds including the JAK2 Inhibitor INCB18424 currently in Phase III of the clinical trials process. If approved, this will be the first FDA approved treatment for myelfibrosis. For more information: Press release BioWorld
MPN NEWS | May 24, 2007
By Mike Nagle 24/05/2007 – At a time when pharma productivity is declining, anticancer specialists Exelixis has started more Phase I clinical trials this year than any other company. The US biotech has today filed an Investigational New Drug (IND) application to US regulators at the Food and Drug Administration (FDA). It is the company’s… Read More »EXELIXIS WINNING PHASE I RACE
MPN NEWS | May 3, 2007
Society’s Prestigious Specialized Center of Research Program Hits $159 Million Mark WHITE PLAINS, N.Y., Oct. 23 /PRNewswire/ — The Leukemia & Lymphoma Society today announced it has awarded four new Specialized Center of Research (SCOR) grants, the Society’s most ambitious and synergistic research initiative, bringing the program’s total funding to $159 million since its inception… Read More »RESEARCHERS ADVANCING BLOOD CANCER THERAPIES RECEIVE $42.75 MILLION IN GRANTS FROM THE LEUKEMIA & LYMPHOMA SOCIETY
MPN NEWS | May 3, 2007
By Lois M. CollinsDeseret Morning News The University of Utah will receive more than $2 million over five years to investigate the causes of several incurable blood disorders. The money is part of a $19.6 million grant from the National Cancer Institute to the Myeloproliferative Disorders Research Consortium, a group of researchers from eight institutions… Read More »UNIVERSITY OF UTAH TO INVESTIGATE BLOOD DISORDERS
Join our community to get the latest research, patient stories, and exclusive content delivered right to your inbox. Plus, when you subscribe, receive the latest NCCN guidelines and resources to support your journey.
JOIN OVER 20,000 SUBSCRIBERS. UNSUBSCRIBE ANYTIME.